Hadi Falahatpisheh Email

VP, Research And Development . ALX Oncology

Current Roles

Employees:
72
Revenue:
$8.4M
About
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
ALX Oncology Address
866 Malcolm Road
Burlingame, CA
Ireland
ALX Oncology Email

Past Companies

ALX OncologyVice President, Research And Development
Biosplice TherapeuticsVice President, Head of Translational Sciences
AbbVieDirector/Research Fellow

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.